Cat. No. 3138
Chemical Name: 4-[[(1R,2E,4E,6Z,9Z)-1-[(1S)-4-Carb
Biological ActivityCysteinyl leukotriene receptor antagonist with equal affinity at both CysLT1 and CysLT2 receptors (pKB values are 6.8 and 6.5 respectively). Competitive antagonist of LTC4- and LTE4-induced contractions of the guinea pig trachea.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Back (2002) Functional characteristics of cysteinyl-leukotriene receptor subtypes. Life Sci. 71 611. PMID: 12072150.
Goranne et al (1996) Cysteinyl leukotriene receptors in the human lung: what's new? TiPS 17 342. PMID: 8979767.
Labat et al (1992) A second cysteinyl leukotriene receptor in human lung. J.Pharmacol.Exp.Ther. 263 800. PMID: 1331415.
If you know of a relevant reference for BAY-u 9773 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses BAY-u 9773 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: BAY-u 9773, supplier, Dual, CysLT1, CysLT2, antagonists, Receptors, leukotrienes, eicosanoids, BAY-u9773, Tocris Bioscience, Leukotriene and Related Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Highly potent P2Y12 antagonistFTY 720
Potent S1P receptor agonist; also immunosuppressantCinacalcet hydrochloride
Calcium-sensing receptor (CaSR) allosteric agonist; also CYP2D2 inhibitor and Ca2+ channel blocker; orally bioavailableAMG 837 hemicalcium salt
Potent free fatty acid receptor 1 (FFA1/GPR40) partial agonistUMB 68
GHB receptor ligandAZD 1283
High affinity P2Y12 antagonistEx 26
Potent and selective S1P1 receptor antagonist
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.